ADMP - Adamis Pharmaceuticals Corporation

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
2.6300
+0.1200 (+4.78%)
At close: 4:00PM EST

2.94 +0.31 (11.79%)
Pre-Market: 7:42AM EST

Stock chart is not supported by your current browser
Previous Close2.5100
Open2.5200
Bid2.91 x 1000
Ask2.97 x 1200
Day's Range2.5000 - 2.6300
52 Week Range2.0100 - 5.1000
Volume41,330
Avg. Volume392,682
Market Cap124.376M
Beta (3Y Monthly)1.58
PE Ratio (TTM)N/A
EPS (TTM)-0.96
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est7.00
Trade prices are not sourced from all markets
  • MarketWatch15 hours ago

    Adamis stock surges on release of EpiPen alternative

    Adamis Pharmaceuticals Corp. shares surged in the extended session Wednesday after the biotech company said its partner Sandoz Inc. launched an alternative to epinephrine auto-injectors like Mylan NV's EpiPen. Adamis shares rallied 14% after hours, after closing up 4.8% at $2.63 in regular trading Wednesday. Adamis said that Sandoz, which is part of Novartis AG , launched Symjepi, a single-dose treatment for allergic reactions including anaphylaxis. "With recent news of epinephrine product shortages in the U.S., we worked together with Sandoz in getting this potentially life-saving quality product into the market as quickly as possible," said Dennis Carlo, chief executive at Adamis, in a statement.

  • GlobeNewswire15 hours ago

    Adamis’ Commercial Partner Launches SYMJEPI™ (epinephrine) in the US

    Adamis Pharmaceuticals Corporation (ADMP) today announced that its marketing and commercial partner, Sandoz Inc. (Sandoz), a Novartis division, has launched SYMJEPI™ (epinephrine) 0.3 mg Injection in the US market for the emergency treatment of allergic reactions (Type 1), including anaphylaxis. SYMJEPI will be rolled out via a phased launch and will initially be available in the institutional setting, an established channel where Sandoz Inc. has significant experience and knowledge, followed by introduction into the retail market.

  • GlobeNewswire14 days ago

    Detailed Research: Economic Perspectives on Biohaven Pharmaceutical Holding, Air Transport Services Group, Pattern Energy Group, First Solar, Limelight Networks, and Adamis Pharmaceuticals — What Drives Growth in Today's Competitive Landscape

    NEW YORK, Jan. 03, 2019 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.

  • Benzinga15 days ago

    Adamis Has 'Favorable' Pipeline Setup, Says Bullish Raymond James

    Adamis Pharmaceuticals Corp (NASDAQ: ADMP ) announced its NDA filing Friday for a fast-dissolving sublingual tadalafil tablet for erectile dysfunction. The Analyst Raymond James analyst Elliot Wilbur maintained ...

  • GlobeNewswire17 days ago

    Adamis Pharmaceuticals Submits New Drug Application to FDA for Its Naloxone Pre-Filled Syringe

    Adamis Pharmaceuticals Corporation (ADMP) today announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration for its naloxone pre-filled single dose syringe (PFS) product candidate. This injection is designed for the treatment of an opioid overdose.  Adamis submitted the NDA pursuant to Section 505(b)(2) of the Food, Drug & Cosmetic Act.

  • ACCESSWIRE17 days ago

    4 Pharma Stocks Gaining Speed on Monday (12/31/18)

    From data-based care solutions to improved treatment options, Premier Health Group (PHGRF) (PHGI), Rite Aid Corporation (RAD), Adamis Pharmaceuticals Corp (ADMP), and Synergy Pharmaceuticals Inc (SGYP) are 4 pharma stocks heating up on Monday. Synergy Pharmaceuticals, Inc (SGYP) a biopharmaceutical company that is largely focused on developing originative gastrointestinal therapies, announced earlier this month that it had entered into an agreement with Bausch Health Companies Inc. through which Bausch Health would acquire substantially all of Synergy's assets, including all rights to TRULANCE®,dolcanatide and related intellectual property, for approximately $200 million in cash.

  • GlobeNewswire19 days ago

    Adamis Pharmaceuticals Submits New Drug Application to FDA for Its Tadalafil Sublingual Tablet

    Adamis Pharmaceuticals Corporation (ADMP) today announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for its fast-dissolving sublingual tadalafil tablet.  This product candidate is designed for the treatment of erectile dysfunction.  Adamis submitted the NDA pursuant to Section 505(b)(2) of the Food, Drug & Cosmetic Act.

  • Adamis Pharmaceuticals (ADMP) Jumps: Stock Rises 5.3%
    Zacks27 days ago

    Adamis Pharmaceuticals (ADMP) Jumps: Stock Rises 5.3%

    Adamis Pharmaceuticals (ADMP) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.

  • Implied Volatility Surging for Adamis Pharmaceuticals (ADMP) Stock Options
    Zackslast month

    Implied Volatility Surging for Adamis Pharmaceuticals (ADMP) Stock Options

    Adamis Pharmaceuticals (ADMP) needs investors to pay close attention to the stock based on moves in the options market lately.

  • Reuterslast month

    Novartis to launch Adamis' EpiPen rival in U.S. next year

    Novartis AG said its U.S. unit Sandoz Inc will launch Adamis Pharmaceuticals Corp's emergency allergy shots next year in the United States, at a price that is about 16 percent below that of similar rival products. Sandoz will start selling the pre-filled epinephrine syringes, SYMJEPI, in the United States in the first quarter of 2019 at a wholesale price of $250 for a two-pack of 0.3 mg injections, Novartis said in a statement.

  • GlobeNewswirelast month

    Adamis Pharmaceuticals Provides Update on the U.S. Launch of SYMJEPI

    Adamis Pharmaceuticals Corporation (ADMP) today provided a business update announcing the U.S. launch of FDA-approved SYMJEPI ™ (epinephrine) 0.3mg Injection is planned for early Q1 2019. Adamis has continued to work closely with Sandoz Inc., a Novartis division, which has exclusive rights to market and distribute Symjepi in the U.S., to prepare for the U.S. market introduction of this life-saving treatment.  Manufacture of commercial batches has been completed and Adamis will begin shipping to Sandoz distribution centers during December to ensure the appropriate supply for launch. SYMJEPI (epinephrine) 0.3mg Injection is indicated for the emergency treatment of allergic reactions (Type 1), including anaphylaxis, to stinging and biting insects, allergen immunotherapy, foods, drugs, diagnostic testing substances and other allergens, as well as idiopathic or exercise-induced anaphylaxis.

  • Teva (TEVA) Launches First Generic Version of Mylan's EpiPen
    Zacks2 months ago

    Teva (TEVA) Launches First Generic Version of Mylan's EpiPen

    Teva (TEVA) launches the first approved generic version of Mylan's (MYL) popular EpiPen (epinephrine) auto-injector for severe allergy treatment in the United States.

  • Adamis Pharmaceuticals (ADMP) Reports Q3 Loss, Lags Revenue Estimates
    Zacks2 months ago

    Adamis Pharmaceuticals (ADMP) Reports Q3 Loss, Lags Revenue Estimates

    Adamis (ADMP) delivered earnings and revenue surprises of -40.00% and -28.83%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?

  • Associated Press2 months ago

    Adamis: 3Q Earnings Snapshot

    On a per-share basis, the San Diego-based company said it had a loss of 21 cents. The results did not meet Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment ...

  • GlobeNewswire2 months ago

    Adamis Pharmaceuticals Announces Third Quarter 2018 Financial Results and Business Update

    SAN DIEGO, Nov. 09, 2018 -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announced financial results for the third quarter ended September 30, 2018 and a business.

  • Adamis Pharmaceuticals (ADMP) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
    Zacks2 months ago

    Adamis Pharmaceuticals (ADMP) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

    Adamis (ADMP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • Simply Wall St.3 months ago

    Could Adamis Pharmaceuticals Corporation’s (NASDAQ:ADMP) Investor Composition Impacts Your Returns?

    A look at the shareholders of Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) can tell us which group is most powerful. Institutions often own shares in more established companies, while it’s not unusual Read More...

  • Adamis Pharmaceuticals (ADMP) in Focus: Stock Moves 8% Higher
    Zacks4 months ago

    Adamis Pharmaceuticals (ADMP) in Focus: Stock Moves 8% Higher

    Adamis Pharmaceuticals (ADMP) saw a big move last session, as its shares jumped 8% on the day, amid huge volumes.

  • ACCESSWIRE4 months ago

    Adamis Pharmaceuticals, FDA PDUFA Action Anticipated, Analyst Coverage

    NEW YORK, NY / ACCESSWIRE / September 26, 2018 / Traders News Source, a leading independent equity research and corporate access firm focused on small and mid-cap public companies is issuing a comprehensive report on Adamis Pharmaceuticals Corporation (ADMP), a specialty biopharmaceutical company primarily focused on developing and commercializing products in various therapeutic areas, including respiratory disease and allergy. The company's Symjepi (epinephrine) Injection 0.3mg, was approved for use in the emergency treatment of acute allergic reactions, including anaphylaxis, and its Symjepi (epinephrine) Injection 0.15mg product is undergoing FDA review. ADMP has selected Novartis unit Sandoz to launch the product in the U.S. (the FDA approved the 0.30 mg version in November 2017).

  • Options Traders Expect Huge Moves in Adamis Pharmaceuticals (ADMP) Stock
    Zacks4 months ago

    Options Traders Expect Huge Moves in Adamis Pharmaceuticals (ADMP) Stock

    Adamis Pharmaceuticals (ADMP) needs investors to pay close attention to the stock based on moves in the options market lately.

  • Implied Volatility Surging for Adamis Pharmaceuticals (ADMP) Stock Options
    Zacks4 months ago

    Implied Volatility Surging for Adamis Pharmaceuticals (ADMP) Stock Options

    Investors need to pay close attention to Adamis Pharmaceuticals (ADMP) stock based on the movements in the options market lately.

  • Mylan’s EpiPen Supply Shortages Continue: What to Expect Ahead
    Market Realist5 months ago

    Mylan’s EpiPen Supply Shortages Continue: What to Expect Ahead

    Mylan’s (MYL) epinephrine auto-injector EpiPen is approved as the first line of treatment for life-threatening allergic reaction anaphylaxis. During its second-quarter earnings release on August 8, Mylan provided an update on its EpiPen supply shortages.